Newsbenzinga
Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…